X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The final results of APLICOV-PC study (Phase I-II), demonstrate the safety of Aplidin (plitidepsin) use in patients with COVID-19 and postulate a positive therapeutic impact on the evolution of the disease.
Lead Product(s): Plitidepsin
Therapeutic Area: Infections and Infectious Diseases Product Name: Aplidin
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2022
Details:
The APLICOV-PC study evaluated three cohorts of hospitalized patients with mild, moderate or severe disease, with three different dose levels of plitidepsin (1.5mg - 2.0mg - 2.5mg), administered on three consecutive days.
Lead Product(s): Plitidepsin
Therapeutic Area: Infections and Infectious Diseases Product Name: Aplidin
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2021
Details:
Pharma Mar has obtained MHRA approval for UK patients to participate in the Phase III NEPTUNO clinical trial, which will determine the efficacy of Aplidin® for the treatment of hospitalized patients with moderate COVID-19 infection.
Lead Product(s): Plitidepsin
Therapeutic Area: Infections and Infectious Diseases Product Name: Aplidin
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2021
Details:
PharmaMar’s cancer drug Aplidin (plitidepsin) has demonstrated ‘potent preclinical efficacy’ against SARS-CoV-2, the virus which causes COVID-19. Aplidin inhibits the eEF1A protein, which is associated with the SARS-CoV-2 virus.
Lead Product(s): Plitidepsin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Apices Soluciones
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
Details:
Plitidepsin shows potent anti-viral effect in preclinical models of original SARS-CoV-2 as well as the new mutant U.K. strain, and by inhibiting a key host protein, has the potential to have antiviral activity against other future mutations and viruses.
Lead Product(s): Plitidepsin
Therapeutic Area: Infections and Infectious Diseases Product Name: Aplidin
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Icahn School of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Details:
There was a substantial reduction in viral load and the C-reactive protein (CRP) in patients, and that 80.7% of patients had been discharged before the 15th day of hospitalisation, and 38.2% before the eighth day.
Lead Product(s): Plitidepsin
Therapeutic Area: Infections and Infectious Diseases Product Name: Aplidin
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Details:
Plitidepsin has showed 2,400~2,800 times higher anti-viral activity than remdesivir.
Lead Product(s): Plitidepsin
Therapeutic Area: Infections and Infectious Diseases Product Name: Aplidin
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaMar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2020
Details:
The objective of the trial is to evaluate the efficacy and safety of plitidepsin in patients with COVID-19 requiring hospital admission.
Lead Product(s): Plitidepsin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
Details:
The goal of the trial is to evaluate the efficacy and safety of plitidepsin in hospitalized patients as a treatment for COVID-19 (SARS-CoV-2).
Lead Product(s): Plitidepsin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2020
Details:
PharmaMar will contact regulatory authorities to analyze the possibilities of studies on patients infected with Covid-19.
Lead Product(s): Plitidepsin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
